|Min SIP Amount||Not Supported|
|NAV||₹22.38 (22 Jun 2021)|
|Fund Started||31 Mar 2016|
|Fund Size||₹57 Cr|
|Gland Pharma Ltd.||Healthcare||Equity||6.4%|
|Cholamandalam Investment & Finance Co. Ltd.||Financial||Equity||6.3%|
|HDFC Bank Ltd.||Financial||Equity||5.7%|
|Reliance Industries Ltd.||Energy||Equity||5.5%|
|Tube Investments Of India Ltd.||Automobile||Equity||5.4%|
|Elgi Equipments Ltd.||Engineering||Equity||5.4%|
|Kennametal India Ltd.||Engineering||Equity||5.3%|
|Larsen & Toubro Ltd.||Construction||Equity||5.2%|
|ICICI Bank Ltd.||Financial||Equity||5.1%|
|Camlin Fine Sciences Ltd.||Chemicals||Equity||5.0%|
SBI Long Term Advantage Fund Series III Direct Growth is a Equity Mutual Fund Scheme launched by SBI Mutual Fund. This scheme was made available to investors on 31 Mar 2016. Rama Iyer Srinivasan, Nidhi Chawla is the Current Fund Manager of SBI Long Term Advantage Fund Series III Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹57 Cr and the Latest NAV as of 22 Jun 2021 is ₹22.38.
The SBI Long Term Advantage Fund Series III Direct Growth is rated Very High risk. Minimum SIP Investment is set to 500.
The scheme seeks to generate capital appreciation over a period of ten years by investing predominantly in equity and equity-related instruments of companies along with income tax benefit.
Upto Rs. 1.5 lac will be tax free under 80C. Lockin of 3 years. Returns will be taxed at 10%.